Clinical Trial Update: Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tislelizumab in combination with chemotherapy as neoadjuvant therapy for stage IIIA-IIIB (N2) lung squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Lung Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Status: UNKNOWN